Statera Biopharma: Restoring Immune Health https://validator.w3.org/feed/docs/rss2.html Statera Biopharma Signs Letter of Intent for Merger with Worksite Labs Test Statera Biopharma Announces Completion of Application Process to Uplist to the OTCQB® Venture Marketplace Home: Statera Biopharma, Inc. Statera Biopharma Receives Positive Nasdaq Listing Determination Statera Biopharma Completes Fiscal 2021 Audit; Files Form 10-K Statera Biopharma Announces Signing of a Binding MOU with Holobeam Technologies to Gain Access to Holobeam’s Disruptive Diagnostic Imaging and Therapeutic Technology for Cancer Patients Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-Q Filing Statera Biopharma Files Form 10-Q and Reaches Agreement with Silverback Capital and AVOF Statera Biopharma Receives Nasdaq Listing Determination; Hearing Requested to Address Filing Delinquency Statera Biopharma Receives Anticipated Notice of Additional Filing Delinquency from Nasdaq Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm Statera Biopharma, Inc. Files Form 12b-25 Statera Biopharma, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022 Pipeline Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-K Filing Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products Statera Biopharma Announces Closing of $5.7 Million Underwritten Public Offering Statera Biopharma Announces Pricing of $5.7 Million Underwritten Public Offering Our Science CORRECTION — Statera Biopharma Announces Proposed Underwritten Public Offering Statera Biopharma Announces Closing of $2.0 Million Registered Direct Offering Statera Biopharma Submits Phase 3 Clinical Trial Protocol to FDA for Investigational Treatment of Pediatric Crohn’s Disease Statera Biopharma, Inc. to Participate in the Benzinga Healthcare Small Cap Conference CORRECTION – Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19 Senior Clinical Trial Manager Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19 Statera Biopharma Announces FDA Lifts Clinical Hold on Entolimod Statera Biopharma, Inc., Announces Central Institutional Review Board Approval of Phase 3 Clinical Trial for Pediatric Crohn’s Disease Statera Biopharma Advances Next-Gen Proprietary Compositions Based on STAT-200 Platform Statera Biopharma Announces Changes to Board of Directors Statera Biopharma Announces First Patient Dosed in Study of STAT-205 for Acute COVID Statera Biopharma Announces Pricing of $2.0 Million Registered Direct Offering About Statera Biopharma Statera Biopharma, Inc. to Participate in the A.G.P. Biotech and Specialty Pharma Conference Statera Biopharma, Inc. to Report Third Quarter 2021 Financial Results Investors Statera Biopharma Provides Third Quarter 2021 Financial and Corporate Update Statera Biopharma Honors Pancreatic Cancer Awareness Month Statera Biopharma, Inc. Announces Institutional Review Board Approves Study of STAT-205 for Acute COVID-19 Statera Biopharma Announces CEO Mike Handley to Speak During Virtual B & T Cell-Mediated Autoimmune Disease Drug Development Summit Statera Biopharma Announces Proposed Underwritten Public Offering Michael Handley on Power Hour – 9/23/21 Statera Biopharma, Inc. to Participate in the Cantor Virtual Global Healthcare Conference Statera Biopharma Announces Revised Preliminary Revenue and Financial Results of Fiscal Year 2021 Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance Agreement Statera BioPharma, Inc. to Ring Nasdaq Stock Market Closing Bell Protected: Careers